Session 1: Navigating the BIOSECURE Act

President Trump signed a revised version of the BIOSECURE Act into law in December 2025, introducing new restrictions on the use of certain foreign biotechnology equipment and service providers.

The amended act maintains the basic prohibition: federal agencies must not enter into, extend, or renew any “contract” with an entity that uses “biotechnology equipment or services” from a “biotechnology company of concern” in performance of their federal contract(s). While the enacted version of the BIOSECURE Act provides important clarifications on questions posed by prior versions of the legislation, including with respect to the impact on government healthcare program contracting, uncertainty remains.

Arnold & Porter will share key issues to watch and play out hypotheticals illustrating the potential impact of the BIOSECURE Act, including updates to the 1260H list and implementation of the act.